-
公开(公告)号：USD938521S1
公开(公告)日：2021-12-14
申请号：US29673985
申请日：2018-12-19
申请人： Glaxo Group Limited
设计人： William Bull , Richard Adams , Philippe Ragot , Carlo Brunelli , Lisa Olivieri , Jeffrey Schons , Alec Johnson
-
2.发明申请公开(公告)号：US20200315919A1
公开(公告)日：2020-10-08
申请号：US16829484
申请日：2020-03-25
申请人： Glaxo Group Limited
摘要： A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy} hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6α,11ß,16α,17α)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.
-
公开(公告)号：US10703814B2
公开(公告)日：2020-07-07
申请号：US16161175
申请日：2018-10-16
申请人： Glaxo Group Limited
IPC分类号： A61K39/395 , C07K16/24 , A61K39/00
摘要： The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
-
公开(公告)号：US20200206237A1
公开(公告)日：2020-07-02
申请号：US16816311
申请日：2020-03-12
申请人： Glaxo Group Limited
发明人： Julie Nicole HAMBLIN , Paul Spencer JONES , Suzanne Elaine KEELING , Joelle LE , Charlotte Jane MITCHELL , Nigel James PARR
IPC分类号： A61K31/5377 , C07D413/14 , A61K45/06 , A61K31/496 , A61K31/497 , A61K31/535
摘要： The invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
-
公开(公告)号：US10466252B2
公开(公告)日：2019-11-05
申请号：US14176231
申请日：2014-02-10
申请人： Glaxo Group Limited
摘要： The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
-
公开(公告)号：USD841740S1
公开(公告)日：2019-02-26
申请号：US29576597
申请日：2016-09-06
申请人： Glaxo Group Limited
设计人： William Bull , Richard Adams , Philippe Ragot , Carlo Brunelli , Lisa Olivieri , Jeffrey Schons , Alec Johnson
-
公开(公告)号：US20180161316A1
公开(公告)日：2018-06-14
申请号：US15817562
申请日：2017-11-20
申请人： Glaxo Group Limited
发明人： Stephen John Atkinson , Michael David Barker , Matthew Campbell , Hawa Diallo , Clement Douault , Neil Stuart Garton , John Liddle , Robert John Sheppard , Ann Louise Walker , Christopher Wellaway , David Matthew Wilson
IPC分类号： A61K31/4545
CPC分类号： A61K31/4545 , A61K31/407 , A61K31/4184 , C07D471/04
摘要： Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R1o is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
-
公开(公告)号：US09850307B2
公开(公告)日：2017-12-26
申请号：US14843250
申请日：2015-09-02
申请人： Glaxo Group Limited
CPC分类号： C07K16/2863 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N1/00 , C12N15/09
摘要： The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
-
公开(公告)号：US09821333B2
公开(公告)日：2017-11-21
申请号：US14223052
申请日：2014-03-24
发明人： James Terence Collins , Thomas Franz Paul Gratzfeld , Heiko Harms , Werner Hertrampf , Richard David Lintern , Gerdhard Niebecker , Allen John Pearson , Paul Kenneth Rand , Karl Heinz Waitz , Karl Gisbert Welp
CPC分类号： B05B11/3004 , B05B1/3436 , B05B11/007 , B05B11/3011 , B05B11/3014 , B05B11/3021 , B05B11/3056 , B05B11/307
摘要： One aspect of the invention provides a component 112, 165 for a fluid dispenser 110 which defines a dosing chamber 120 for a piston member 114 to stroke in and has an end 160 adapted for engaging a fluid outlet 152 of the fluid dispenser or a seal 154 which overlies the fluid outlet 152 to selectively close and open the fluid outlet 152 or seal 154. Other aspects are disclosed herein.
-
公开(公告)号：US09795561B2
公开(公告)日：2017-10-24
申请号：US14651988
申请日：2013-12-17
申请人： Glaxo Group Limited
IPC分类号： A61K31/569 , A61K47/26 , A61K31/137 , A61K31/439 , A61K31/56 , A61K9/00 , A61J1/03
CPC分类号： A61K9/0075 , A61J1/035 , A61K31/137 , A61K31/439 , A61K31/56 , A61K31/569 , A61K47/26 , A61K2300/00
摘要： The present invention is directed to pharmaceutical combination products comprising a muscarinic acetylcholine receptor antagonist, fluticasone propionate and salmeterol xinafoate, and to their use in the treatment of inflammatory or respiratory tract diseases.
-
-
-
-
-
-
-
-
-
搜索结果
238 条记录 (耗时 0.031 秒)
